Physician profile
Michael Rk Jacoby
NPI 1346354198
$243,007.15
in general payments reported to CMS, 2019-2025
33 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $40K · 2021: $54K · 2022: $42K · 2023: $33K · 2024: $23K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Travel and Lodging: $9,254 · Food and Beverage: $3,002 · Education: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,362.50 |
| Travel and Lodging | $9,253.98 |
| Food and Beverage | $3,001.51 |
| Education | $405.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $109,676.90 | 2019-2025 | |
| Lilly USA, LLC | $31,173.55 | 2019-2021 | |
| Amgen INC. | $30,033.88 | 2019-2022 | |
| Allergan, INC. | $26,869.46 | 2020-2021 | |
| Pfizer INC. | $24,497.00 | 2019-2025 | |
| Lundbeck LLC | $9,887.95 | 2021-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $7,375.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $1,176.86 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $820.70 | 2019-2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $258.99 | 2019-2021 | |
| Genentech USA, INC. | $149.51 | 2019 | |
| Sunovion Pharmaceuticals INC. | $141.59 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $122.95 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $103.67 | 2021 | |
| Supernus Pharmaceuticals, INC. | $86.65 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $79.16 | 2019 | |
| Ucb, INC. | $74.75 | 2019-2020 | |
| Biogen, INC. | $53.99 | 2019 | |
| Argenx US, INC. | $52.80 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Tg Therapeutics, INC. | $46.58 | 2024 | |
| Eisai INC. | $39.91 | 2019 | |
| Sk Life Science, INC. | $37.59 | 2024 | |
| Adamas Pharmaceuticals, INC. | $34.40 | 2019 | |
| Csl Behring | $31.77 | 2025 | Hizentra |
| Alnylam Pharmaceuticals INC. | $31.75 | 2019 | |
| Ge Healthcare | $29.26 | 2019 | |
| Promius Pharma LLC | $22.35 | 2019 | |
| Merz North America, INC. | $18.29 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.13 | 2025 | Wainua |
| Kyowa Kirin, INC. | $15.96 | 2020 | |
| Tanabe Pharma America, INC. | $15.90 | 2019 | |
| Upsher-Smith Laboratories LLC | $15.51 | 2019 | |
| Mdd US Operations, LLC | $14.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jacoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.